Roche (RHHBY - Analyst Report) recently announced that its new diagnostic test, Elecsys Syphilis immunoassay, is now available in the markets.
The test carries a CE mark. The new test will enable specialists to identify syphilis in routine samples and donated blood.
The test is designed to meet the rising needs of clinical laboratories for reliable and efficient detection of syphilis, which is more prevalent in developing countries but has become a cause of concern in developed nations as well.
The test is highly sensitive and minimizes the likelihood of missing syphilis infections.
The new test not only strengthens Roche’s diagnostics portfolio in the serology market but also expands its immunoassay portfolio in infectious disease.
We remind investors that Roche specializes in drugs for oncology, immunology, and infectious diseases. Apart from providing therapeutic products and services for diverse medical needs, Roche also focuses on innovative diagnostic solutions for the early detection and treatment of diseases.
Roche has a broad portfolio of diagnostic tests with more than a hundred high-quality Elecsys assays for immune testing along with a new generation of fully automated cobas analyzers for improved medical decision making, scheduling and efficiency.
We are encouraged by Roche’s efforts to strengthen its Diagnostic division.
The Diagnostics division generated sales of $10.5 billion in 2013, up 4% from a year ago. Roche introduced a range of new instruments and tests, including the cobas 8100 and a new HPV test for cervical cancer. The introduction of new tests will further boost the sales of this division.
Roche currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks include Novo Nordisk (NVO - Analyst Report), Shire (SHPG - Analyst Report) and Salix Pharmaceuticals (SLXP - Analyst Report). While Shire and Salix Pharmaceuticals hold a Zacks Rank #1 (Strong Buy), Novo Nordisk carries a Zacks Rank #2 (Buy).